PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020076
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2020076
Lung Cancer Screening Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of lung cancer screening Market
The global lung cancer screening market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.16 billion in 2026, reaching USD 8.67 billion by 2034, registering a CAGR of 9.61% during 2026-2034. North America dominated the market with a 55.13% share in 2025, driven by strong screening programs and advanced healthcare infrastructure.
Lung cancer remains one of the most prevalent and fatal cancers worldwide, primarily linked to tobacco consumption. Early detection through screening plays a critical role in reducing mortality, which is significantly boosting the adoption of advanced diagnostic technologies globally.
Market Trends
Technological Advancements in Screening
The market is witnessing rapid technological progress, particularly in screening methods such as low-dose computed tomography (LDCT), liquid biopsy, and AI-based diagnostic tools. These innovations are improving early detection rates while reducing the need for invasive procedures.
Emerging technologies such as nanoparticle-based sensors and AI-assisted imaging are transforming screening accuracy and efficiency. Additionally, the development of liquid biopsy tests is enabling non-invasive cancer detection, making screening more accessible and patient-friendly.
Market Growth Factors
Rising Prevalence of Lung Cancer
The increasing global incidence of lung cancer, largely due to smoking and lifestyle changes, is a major driver of market growth. Growing awareness regarding early diagnosis and the rising number of screening initiatives by healthcare organizations are further supporting market expansion.
Government programs and awareness campaigns are encouraging high-risk populations to undergo regular screening, thereby increasing the number of diagnostic procedures conducted annually.
Growing Adoption of Advanced Diagnostic Tools
The increasing use of advanced imaging technologies, coupled with favorable reimbursement policies in developed countries, is driving the adoption of screening solutions. Collaborations between biotechnology and healthcare companies are also fostering innovation in diagnostic techniques.
Restraining Factors
High Cost of Screening Tests
Despite technological advancements, the high cost associated with screening procedures, especially CT scans, limits their accessibility in low- and middle-income countries. Limited insurance coverage and inadequate healthcare infrastructure further restrict widespread adoption.
Additionally, the shortage of skilled radiologists and diagnostic professionals in developing regions poses a challenge to market growth.
Market Segmentation Analysis
By Cancer Type
The market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- The NSCLC segment dominates and is projected to hold 87.8% market share in 2026, owing to its higher prevalence globally.
- The SCLC segment also contributes significantly due to rising awareness and screening initiatives.
By Diagnosis Type
The market is divided into low-dose spiral CT scans and chest X-rays.
- The low-dose CT scan segment dominates with 93.94% share in 2026, driven by higher accuracy and proven mortality reduction benefits.
- Chest X-rays are witnessing declining adoption due to lower effectiveness.
By End-user
The market includes hospitals & clinics and diagnostic centers.
- Hospitals & clinics lead the market, accounting for 70.79% share in 2026, due to better infrastructure and higher patient preference.
- Diagnostic centers are expected to grow steadily with increasing collaborations and service expansion.
Regional Insights
North America
North America accounted for USD 2.11 billion in 2025 and is projected to reach USD 2.31 billion in 2026. Strong screening programs and high disease prevalence support regional dominance.
Europe
Europe held USD 1.15 billion in 2025 and is expected to grow to USD 1.24 billion in 2026. Growth is driven by rising smoking rates and well-established healthcare systems.
Asia Pacific
Asia Pacific generated USD 0.38 billion in 2025 and is projected to reach USD 0.41 billion in 2026. Increasing tobacco consumption and government initiatives are fueling growth.
Rest of the World
- Latin America: USD 0.16 billion (2025) -> USD 0.17 billion (2026)
- Middle East & Africa: USD 0.03 billion (2025) -> USD 0.03 billion (2026)
These regions show gradual growth due to improving healthcare infrastructure.
Key Companies
Leading players in the market include Koninklijke Philips N.V., Siemens Healthineers AG, Canon Medical Systems Corporation, GE Healthcare, and FUJIFILM Holdings Corporation. These companies focus on innovation, product launches, and strategic partnerships to strengthen their market position.
Key Industry Developments
- In 2024, new screening programs and clinical trials were launched to improve early detection.
- AI-based diagnostic tools and imaging technologies received regulatory approvals.
- Companies are increasingly focusing on non-invasive screening solutions such as liquid biopsies.
Conclusion
The lung cancer screening market is poised for strong growth, increasing from USD 3.84 billion in 2025 to USD 8.67 billion by 2034. Rising cancer prevalence, technological advancements, and government support for early diagnosis are key growth drivers. Although high costs and limited accessibility may hinder adoption in some regions, ongoing innovations and expanding screening programs will significantly enhance early detection and improve patient outcomes globally.
Growth Rate CAGR of 9.61% from 2026-2034
Segmentation By Cancer Type
- Non-small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer
By Diagnosis Type
- Low Dose Spiral CT Scan
- Chest X-ray
By End User
- Hospitals & Clinics
- Diagnostic Centers
By Geography
- North America (By Cancer Type, By Diagnosis Type, By End User, and By Country)
- U.S.
- Canada
- Europe (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Incidence of Lung Cancer, By Key Region, 2025
- 4.2. Key Industry Developments, Merger, Acquisitions, and Product Launches
- 4.3. Regulatory Scenario Imposed on the Development of Lung Cancer Screening in U.S., Europe, and Asia
- 4.4. Technological Advancements in Lung Cancer Screening
- 4.5. Impact of COVID-19 on Lung Cancer Screening
5. Global Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Cancer Type
- 5.1.1. Non-small Cell Lung Cancer (NSCLC)
- 5.1.2. Small Cell Lung Cancer
- 5.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 5.2.1. Low Dose Spiral CT scan
- 5.2.2. Chest X-ray
- 5.3. Market Analysis, Insights and Forecast - By End User
- 5.3.1. Hospitals & Clinics
- 5.3.2. Diagnostic Centers
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Cancer Type
- 6.1.1. Non-small Cell Lung Cancer (NSCLC)
- 6.1.2. Small Cell Lung Cancer
- 6.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 6.2.1. Low Dose Spiral CT scan
- 6.2.2. Chest X-ray
- 6.3. Market Analysis, Insights and Forecast - By End User
- 6.3.1. Hospitals & Clinics
- 6.3.2. Diagnostic Centers
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Cancer Type
- 7.1.1. Non-small Cell Lung Cancer (NSCLC)
- 7.1.2. Small Cell Lung Cancer
- 7.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 7.2.1. Low Dose Spiral CT scan
- 7.2.2. Chest X-ray
- 7.3. Market Analysis, Insights and Forecast - By End User
- 7.3.1. Hospitals & Clinics
- 7.3.2. Diagnostic Centers
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Cancer Type
- 8.1.1. Non-small Cell Lung Cancer (NSCLC)
- 8.1.2. Small Cell Lung Cancer
- 8.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 8.2.1. Low Dose Spiral CT scan
- 8.2.2. Chest X-ray
- 8.3. Market Analysis, Insights and Forecast - By End User
- 8.3.1. Hospitals & Clinics
- 8.3.2. Diagnostic Centers
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Cancer Type
- 9.1.1. Non-small Cell Lung Cancer (NSCLC)
- 9.1.2. Small Cell Lung Cancer
- 9.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 9.2.1. Low Dose Spiral CT scan
- 9.2.2. Chest X-ray
- 9.3. Market Analysis, Insights and Forecast - By End User
- 9.3.1. Hospitals & Clinics
- 9.3.2. Diagnostic Centers
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Cancer Type
- 10.1.1. Non-small Cell Lung Cancer (NSCLC)
- 10.1.2. Small Cell Lung Cancer
- 10.2. Market Analysis, Insights and Forecast - By Diagnosis Type
- 10.2.1. Low Dose Spiral CT scan
- 10.2.2. Chest X-ray
- 10.3. Market Analysis, Insights and Forecast - By End User
- 10.3.1. Hospitals & Clinics
- 10.3.2. Diagnostic Centers
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
- 10.4.1. GCC Countries
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Koninklijke Philips N.V.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Siemens Healthineers AG
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. GE Healthcare (General Electric Company)
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Nuance Communications, Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Eon
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. PenRad Technologies, Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Volpara Solutions Limited.
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Canon Medical Systems Corporation
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. FUJIFILM Holdings Corporation
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Medtronic
- 11.2.10.1. Overview
- 11.2.10.2. Products & Services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.1. Koninklijke Philips N.V.
List of Tables
- Table 01: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 02: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 03: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 04: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Region, 2021-2034
- Table 05: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 06: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 07: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 08: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country, 2021-2034
- Table 09: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 10: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 11: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 12: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 13: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 14: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 15: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 16: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 17: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 18: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 19: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 20: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
- Table 22: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
- Table 23: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
- Table 24: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 01: Global Lung Cancer Screening Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
- Figure 02: Global Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025 & 2034
- Figure 03: Global Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025 & 2034
- Figure 04: Global Lung Cancer Screening Market Value Share (%), by End User, 2025 & 2034
- Figure 05: Global Lung Cancer Screening Market Value (USD Billion), by Region, 2025 & 2034
- Figure 06: North America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
- Figure 07: North America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
- Figure 08: North America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
- Figure 09: North America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
- Figure 10: North America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 11: North America Lung Cancer Screening Market Value Share (%), by End User, 2025
- Figure 12: North America Lung Cancer Screening Market Value (USD Billion), By Country, 2025 & 2034
- Figure 13: North America Lung Cancer Screening Market Value Share (%), By Country, 2025
- Figure 14: Europe Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
- Figure 15: Europe Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
- Figure 16: Europe Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
- Figure 17: Europe Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
- Figure 18: Europe Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 19: Europe Lung Cancer Screening Market Value Share (%), by End User, 2025
- Figure 20: Europe Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
- Figure 21: Europe Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
- Figure 22: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
- Figure 23: Asia Pacific Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
- Figure 24: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
- Figure 25: Asia Pacific Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
- Figure 26: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 27: Asia Pacific Lung Cancer Screening Market Value Share (%), by End User, 2025
- Figure 28: Asia Pacific Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
- Figure 29: Asia Pacific Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
- Figure 30: Latin America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
- Figure 31: Latin America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
- Figure 32: Latin America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
- Figure 33: Latin America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
- Figure 34: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 35: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 36: Latin America Lung Cancer Screening Market Value Share (%), by End User, 2025
- Figure 37: Latin America Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
- Figure 38: Latin America Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
- Figure 39: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
- Figure 40: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
- Figure 41: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
- Figure 42: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
- Figure 43: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
- Figure 44: Middle East & Africa Lung Cancer Screening Market Value Share (%), by End User, 2025
- Figure 45: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Middle East & Africa Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
